GET DAILY SIGNALSTG Therapeutics (TGTX) Delivers Strong Q3 2026 Revenue Growth of 61%
Key Takeaways
- Total global revenue reached approximately $260 million in the third quarter of 2026, up 61% year over year and ahead of consensus estimates of roughly $245 million.
- U.S. BRIUMVI net product revenue rose 52% to $233 million, marking the product's 14th consecutive quarter of sequential growth.
- GAAP diluted earnings per share (EPS) came in at $0.35, modestly below the higher end of analyst estimates but compared with $2.43 in the prior-year quarter, which was lifted by a one-time tax benefit.
- Operating income climbed to $86 million, up from $29 million in the third quarter of 2025.
- TG Therapeutics raised its full-year 2026 outlook, now targeting roughly $1 billion in total global revenue and $915–920 million in U.S. BRIUMVI net product revenue.
- The company ended the quarter with about $557 million in cash, equivalents, and investment securities and repurchased $100 million of its own stock.
Why These Results Matter
TG Therapeutics is a commercial-stage biotech focused on treatments for B-cell diseases, with its multiple sclerosis (MS) therapy BRIUMVI (ublituximab) driving essentially all of its growth. The third quarter of 2026 was closely watched because it tests whether BRIUMVI's rapid uptake can continue as the drug moves deeper into a competitive MS market. Coming off strong first-half results and a series of guidance increases, investors were looking for evidence that demand remains durable and that the company's profitability is scaling alongside revenue. The results matter beyond a single quarter: they inform whether TG Therapeutics can sustain its growth trajectory while funding a pipeline that includes a subcutaneous version of BRIUMVI and earlier-stage programs.
Reported Results
For the quarter ended September 30, 2026, TG Therapeutics reported total revenue of approximately $260 million, a 61% increase from about $162 million in the prior-year period and above the consensus estimate of roughly $245 million. Total net product revenue was about $240 million, including $233 million from U.S. BRIUMVI sales (up 52% year over year) and $7.4 million in product sales to ex-U.S. partner Neuraxpharm. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
License, milestone, royalty, and other revenue totaled about $19.9 million, including a $10 million sales milestone from the ex-U.S. partner. U.S. BRIUMVI gross margin held at 87%, while consolidated gross margin was about 84%. Operating income reached $86 million, up from $29 million a year earlier. Net income was approximately $55.5 million, or $0.35 per diluted share; the prior-year quarter's $2.43 diluted EPS reflected a roughly $365 million non-cash income tax benefit from the release of a deferred tax asset valuation allowance.
Management raised full-year 2026 guidance, lifting total global revenue expectations to approximately $1 billion (from $950 million) and U.S. BRIUMVI net product revenue to $915–920 million (from $890–905 million), while keeping its full-year operating expense guidance of $450–500 million unchanged.
Market Reaction and Investor Sentiment
Shares of TG Therapeutics responded positively to the report, with the stock advancing in the session following the November 9, 2026 release. The combination of a 61% revenue increase, a top-line beat, and raised full-year guidance outweighed the modest EPS shortfall relative to the higher end of consensus, which analysts largely attributed to the prior-year tax-benefit comparison rather than underlying weakness. The 14th consecutive quarter of sequential BRIUMVI growth reinforced the view that demand momentum remains intact, while the $100 million share repurchase signaled management's confidence in the company's valuation.
Forward Outlook and Key Factors to Monitor
The raised guidance points to a company gaining operating leverage as BRIUMVI scales. Investors will be watching whether U.S. BRIUMVI can sustain double-digit growth and whether gross margins hold near current levels as volumes rise.
Beyond the commercial franchise, several catalysts loom. Topline data from the Phase 3 subcutaneous BRIUMVI program is expected around year-end 2026 or early 2027, with a potential launch targeted for 2028 if results are positive and regulatory approval follows. A subcutaneous option could meaningfully expand the addressable market by moving into self-administered settings.
Additional items to monitor include the Phase 3 ENHANCE study of a simplified BRIUMVI dosing schedule, early-stage work in myasthenia gravis, and progress on azer-cel, the company's allogeneic anti-CD19 CAR-T program in progressive MS. Cost discipline will also be in focus, with management keeping full-year operating expense guidance unchanged despite the higher revenue outlook. Together, these factors will help determine whether the current growth trajectory can be extended through 2027 and beyond.
Using Tickeron’s AI Screener for My Research
In my own analysis of names like TG Therapeutics, I frequently rely on Tickeron’s AI Screener to quickly filter for comparable setups across technical patterns, fundamentals, and momentum signals. It helps surface relevant peers and monitor shifts in real time without manual effort, which keeps my workflow efficient when evaluating biotech growth stories.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TGTX in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TGTX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 253 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 177 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 62 cases where TGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.159) is normal, around the industry mean (3.498). P/E Ratio (19.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement